CTRI/2020/12/029575尚未招募3 期
A study to assess the safety and efficacy of add-on Unani regimen in preventing the progression of severity of the disease in mild to moderate symptomatic COVID-19 RT-PCR positive cases
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. On the day of admission patients who have been tested positive with SARS-CoV2 virus through RT PCR
- •2. Patients with mild symptoms
- •Patients with moderate symptoms with respiratory rate < 30 per minute and oxygen saturation > 90%
排除标准
- •1.COVID-19 patients with symptoms classified as severe or critical.
- •2.Suspected COVID-19, not tested positive for COVID-19 by RT-PCR
- •3.Persons with severe primary respiratory disease or pneumonia
- •4.Pregnant and lactating women
- •5.Persons with severe illness such as Cancer, Heart Disease, Stroke, Mental disorder, etc., and who are considered to be excluded from the study as evaluated by the Investigators
- •6.COVID-19 positive cases simultaneously participating as subjects in the interventional arm of other COVID-19 clinical trials
研究者
相似试验
已完成
不适用
Investigation of efficacy and safety of add-on therapy with DPP-4 inhibitor in type 2 diabetic patients poorly controlled with basal supported oral therapyType 2 diabetesJPRN-UMIN000010849Department of Metabolism & Endocrinology Juntendo University Graduate School of Medicine40
招募中
2 期
Evaluation of the efficacy and safety of lacosamide to duloxetine in the treatment of taxanes- induced peripheral neuropathyTaxane-induced neuropathy.IRCT20090613002027N21Mazandaran University of Medical Sciences60
已完成
2 期
Olanzapine as a medication to reduce nausea and vomiting following chemotherapy in childrePalliative care.Encounter for palliative careIRCT20090613002027N14Sari University of Medical Sciences49
进行中（未招募）
不适用
A trial, in which subjects with type 2 diabetes, who qualify for treatment intensification, are given insulin degludec and, additionally, either liraglutide or insulin aspart, both in combination with metformin, with the largest meal. The purpose is to compare efficacy and safety of these two treatments.EUCTR2011-001493-25-ATovo Nordisk A/S420
进行中（未招募）
不适用
A trial, in which subjects with type 2 diabetes, who qualify for treatment intensification, are given insulin degludec and, additionally, either liraglutide or insulin aspart, both in combination with metformin, with the largest meal. The purpose is to compare efficacy and safety of these two treatments.Type 2 diabetesMedDRA version: 14.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-001493-25-DEovo Nordisk A/S420